Exponent, Inc. (EXPO)
NEUTRALFundamental
65
Preço
$69.78
Capitalização de Mercado
$3.39B
Parte 1 · Quanto vale a empresa
Visão Geral
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$632M
Últimos 12 meses (até 03/07/2026)
Resultado Líquido
$112M
Últimos 12 meses (até 03/07/2026)
Fluxo de Caixa Livre
$122M
Capital Próprio Total
$390M
Passivo Total
$387M
Rácio de Liquidez
1.98
Cobertura de Juros
-
Dívida/EBITDA
0.62
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$63.65
Preço Atual
$69.78
Margem de Segurança
-9.6%
Intervalo de Valor Justo
$45.42 - $81.89
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
31.88
ROE
27.2%
Rácio P/B
11.66
P/FCF
31.00
Margem Bruta
-
ROIC
20.4%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
20.4%
WACC
8.1%
ROIC − WACC
+12.3 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critérios de Análise Fundamental
Aprovado (18)
- EPS shows upward trend
- Price CAGR 8.82%
- ROIC 20.4%
- Debt/Equity ratio
- Operating Margin 20.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 27.9%
- Revenue Growth 5Y 7.8%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 4.3%
- Earnings Quality (OCF/NI) 1.06
- Share Dilution -0.9%
- Piotroski F-Score 5/9
Reprovado (7)
- EPS CAGR 2.16%
- P/FCF 31.00
- P/B Ratio 11.66
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 4.90
- Net Margin Trend 17.7% vs 18.3%
Indisponível (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Catherine Ford Corrigan P.E., Ph.D. | CEO & Director | 56 |
| Mr. Richard L. Schlenker Jr. | Executive VP, Corporate Secretary & Director | 59 |
| Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D. | Group Vice President | 56 |
| Dr. Joseph Rakow Ph.D. | Group Vice President | 48 |
| Dr. Joseph Sala Ph.D. | Group Vice President | 48 |
| Dr. John D. Pye P.E., Ph.D. | President | 54 |
| Dr. Bernard Ross P.E., Ph.D. | Co-Founder & Principal Engineer | - |
| Mr. Eric R. Anderson | Chief Financial Officer | 50 |
| Ms. Gina Flynn | VP of Legal & General Counsel | - |
| Mr. Brian Kundert | Chief Human Resources Officer | 50 |
Risco de Auditoria
9
Risco do Conselho
2
Risco de Remuneração
4
Risco dos Direitos dos Acionistas
2
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for EXPO, sourced from Markets Gazette.